

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Vonoprazan 20 mg (Voquezna 20 mg)

Notes:

- Quantity Limits: Yes
- ^ Adequate trial is defined as 14-day treatment duration
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation
- **Treatment duration = 2 months for erosive or non-erosive gastroesophageal reflux disease and 14 days for *H. pylori* treatment

Initiation (new start) criteria and criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:
Non-formulary **vonoprazan 20 mg tablet (Voquezna 20 mg)** will be covered for on the prescription drug benefit for the appropriate treatment duration** when the following criteria are met:

1. Prescriber is a gastroenterologist and patient has a diagnosis of erosive or non-erosive gastroesophageal reflux disease
 - Patient has failed an adequate trial^, or has an allergy or intolerance* to the following medications:
 - Omeprazole (at least 40 mg per day)
 - Pantoprazole (at least 40 mg per day)
 - Lansoprazole (at least 30 mg per day)
 - Rabeprazole (at least 20 mg per day)
 - Esomeprazole (at least 40 mg per day)
 - Dexlansoprazole (criteria based) (at least 60 mg per day)
2. Prescriber is a gastroenterologist and patient has a diagnosis of treatment-naïve *H. pylori* infection
 - Vonoprazan is prescribed in conjunction with amoxicillin
 - Patient has an allergy or intolerance to the following medication regimens:
 - Optimized bismuth quadruple therapy (14-day course of bismuth subsalicylate, tetracycline, metronidazole, PPI)
 - Rifabutin triple therapy (14-day course of rifabutin, amoxicillin, PPI)
3. Prescriber is a gastroenterologist and patient has a diagnosis of treatment-experienced *H. pylori* infection
 - Vonoprazan is prescribed in conjunction with amoxicillin and clarithromycin

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Vonoprazan 20 mg (Voquezna 20 mg)

- Patient has failed an adequate trial[^] of or patient has an allergy or intolerance* to the following medication regimens:
 - Optimized bismuth quadruple therapy (14-day course of bismuth subsalicylate, tetracycline, metronidazole, PPI)
 - Rifabutin triple therapy (14-day course of rifabutin, amoxicillin, PPI)
 - Levofloxacin triple therapy (14-day course of levofloxacin, metronidazole and PPI **OR** levofloxacin, amoxicillin and PPI) unless patient has confirmed levofloxacin-resistant infection
- Patient has a documented allergy or intolerance* to proton pump inhibitors and is unable to take clarithromycin triple therapy (14-day course of clarithromycin, amoxicillin and PPI)